Developing patient-specificImmunotherapies to Treat Cancer & Vaccines for preventing Infectious Diseaseusing membrane anchored-Biological adjuvants
Our proprietary biological adjuvant platform technology involves anchoring cytokine and immunostimulatory protein adjuvants onto biological membranes such as tumor derived membrane vesicles and virus like particles. Our biological adjuvants are linked to the antigen source to provide an enhanced immune response and stimulate specific immune pathways to achieve the desired immune response.Metaclipse Biopharma intends to commercialize its products in India after establishing safety and effectiveness.
Empowerthe Immune System to Eliminate Cancer
Membrex™ immunotherapy platform
Metaclipse Biopharmahas licensed d a novel personalized vaccine immunotherapy platform, Membrex™ from Metaclipse Therapeutics USA as a monotherapy and as part of combination therapy for the treatment oftriple negative breast cancer (TNBC), and other solid tumors such as head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC) and HER2-positive breast cancer.
Phase 1 clinical trials for Membrex™ immunotherapy for triple negative breast cancer (TNBC) and head and neck squamous cell carcinoma (HNSCC) are expected to begin patient enrollment in the first quarter of 2025 in USA. Metaclipse Biopharma is conducting feasibility studies followed by clinical trials in India to bring this innovative and cost-effective personalized cancer immunotherapy to TNBC or HNSCC patientsin India who currentlydo not have a treatment option that addresses the high level of tumor heterogeneity.
How Membrex™ immunotherapy is designed to work
Immune escape is one of major contributing factors for cancer progression. Further, cancer is highly heterogeneous and varies patient to patient. Membrex™, our cancer immunotherapy tailored to each patient and their specific tumor, consists of ‘membrane vesicles’ prepared from a patient’s tumor tissue modified using proven immunostimulatory proteins. After intradermal injection, Membrex™ delivers both immunostimulatory proteins and an array of patient-specific tumor-antigens simultaneously to the immune system resulting in robust antitumor immunity and suppression of cancer.
Membrex™ advantages over competitive immunotherapies
• Easy to Manufacture without the need of establishment of immortalized tumor cell lines, T cell cultures, or the use of viral vectors
• Includes majority of tumor antigens, addressing tumor heterogeneity
• Rapid, cost-effective manufacture and administration of the therapy to the patient within 3 weeks
• Particulate in nature, so optimal for uptake and processing by immune cells
• Physical linkage of biological adjuvants to tumor antigen source enhances immune response with a favorable safety profile
• Functions in combination with immune checkpoint inhibitors (ICI) and enhances response rates for ICI-resistant cancers.
Developing Membrane-Anchored Biological Adjuvants for Vaccines Against Infectious Diseases
VaxRex™ vaccine platform
We are developing a vaccine platform, VaxRex™, for infectious disease prevention consisting of ‘virus-like particles’ (VLP) modified using our proven biological adjuvants. After administration, VaxRex™ delivers both biological adjuvants and virus-specific antigens simultaneously in a particulate form to the immune system. VaxRex™ induced a robust virus-specific immune response in both young and aged animals. Metaclipse anticipates VaxRex™ will reduce infection rate and disease severity, especially for the elderly and immunocompromised individuals.
VaxRex™ advantages
• Broad applicability, including vaccines for enveloped viruses such as influenza, SARS-CoV-2, and HIV
• Rapid manufacture of the vaccine with the ability to achieve much higher surface concentrations of membrane-anchored biological adjuvants in comparison to gene transfer
• Easily degrade in the system, suggesting they do not accumulate in the body upon repeated vaccinations, avoiding chronic side effects
• Physical linkage of membrane-bound adjuvants with antigens yields potent immune response and favorable safety profile